Concomitant inhibition of the thioredoxin system and nonhomologous DNA repair potently sensitizes Philadelphia‐positive lymphoid leukemia to tyrosine kinase inhibitorsLukasz Komorowski, Małgorzata Firczuk, Kacper Szczygiel et al.|HemaSphere|2024Cited by 3
Asciminib stands out as the superior tyrosine kinase inhibitor to combine with anti-CD20 monoclonal antibodies for the treatment of CD20+ Philadelphia-positive B-cell precursor acute lymphoblastic leukemia in preclinical modelsKrzysztof Domka, Małgorzata Firczuk, Agnieszka Dąbkowska et al.|Haematologica|2024Cited by 1